The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.

U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

These under-$10 biotech stocks are within range of triggering breakout trades.

Endocyte (ECYT) shares are down after being downgraded to 'hold' by analysts at Brean Capital.

Trade-Ideas LLC identified Endocyte (ECYT) as a pre-market mover with heavy volume candidate

Trade-Ideas LLC identified Endocyte (ECYT) as a strong on high relative volume candidate

Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate

This machine is expected to be produced "as quickly as possible" at a high volume and at low cost.

The fast-food giant has been hesitant to make changes like this, but Wendy's bold move may have forced it to.

The billionaire wants to create a "future of abundance" by mass-producing humanoid robots.